Completion of Acquisition

RNS Number : 8958A
Venture Life Group PLC
24 January 2020

24 January 2020

Venture Life Group plc

("Venture Life" or the "Group")

Completion of Acquisition

Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces that the conditions to achieve completion of its acquisition of PharmaSource BV as previously announced on 19th December 2019 have now been met and the Completion has taken place today.

For further information, please contact:

Venture Life Group plc

+44(0) 1344 578004


Jerry Randall, Chief Executive Officer




Cenkos Securities plc (Nomad and Broker)

+44(0)20 7397 8900


Mark Connelly / Stephen Keys / Cameron MacRitchie (Corporate Finance)


Russell Kerr / Michael Johnson (Sales)




  Alma PR

 +44(0)20 3405 0208


Hilary Buchanan / Helena Bogle / Jessica Joynson / Kieran Breheny



 About Venture Life (

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in both the UK and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare and proctology and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK these are supplied direct by the company, outside of the UK they are supplied by the Group's international distribution partners. 

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
UK 100